Brief: Kala Bio Receives Notice Of Event Of Default From Oxford Finance Llc - SEC Filing
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
Brief: Kala Bio Approves 51% Workforce Reduction - SEC Filing
Kala Bio scraps development of eye disease drug after trial failure (updated)
Brief: Kala Bio Announces Topline Results From Chase Phase 2B Clinical Trial
KALA BIO scraps development of eye disease drug after trial failure
Kala Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Kala Bio Q2 EPS USD -1.71
Kala Bio Inc Expected To Post A Loss Of $1.70 A Share: Earnings Preview
Brief: Kala Bio Q1 EPS USD -1.41
Kala Bio Inc Expected To Post A Loss Of $2.03 A Share: Earnings Preview
Brief: Kala Bio Q4 EPS USD -1.74
Kala Bio Inc Expected To Post A Loss Of $2.28 A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Chefs' Warehouse, Aptose Biosciences, Electromed
Kala Bio tumbles after CEO resignation
Brief: Kala Bio Files For Resale Of Up To 1.67 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Brief: KALA BIO Announces $10,750,000 Private Placement
Kala Bio Inc Reports Results For The Quarter: Earnings Summary
Kala Bio Inc Expected To Post A Loss Of $2.43 A Share: Earnings Preview